Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trials

Medical device clinical trials from ClinicalTrials.gov

Trial RECRUITING

Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients

NCT NCT06270238

Start 2024-02-13

View Details →

Trial RECRUITING

Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings

NCT NCT06268405

Start 2023-09-21

View Details →

Trial COMPLETED

The STRENGTHEN Study

NCT NCT06267521

Start 2024-03-06

View Details →

Trial COMPLETED

Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis

NCT NCT06264141

Start 2024-01-16

View Details →

Trial RECRUITING

Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation

NCT NCT06263608

Start 2024-02-23

View Details →

Trial COMPLETED

Semaglutide and Preoperative Residual Gastric Volumes

NCT NCT06263595

Start 2024-05-31

View Details →

Trial RECRUITING

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior

NCT NCT06260683

Start 2024-04-10

View Details →

Trial COMPLETED

Using Low Intensity Focused Ultrasound to Modulate Deep Brain Areas for Tremor Control in Parkinson's Disease Patients.

NCT NCT06259708

Start 2024-03-01

View Details →

Trial RECRUITING

Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease

NCT NCT06259019

Start 2023-09-14

View Details →

Trial COMPLETED

taVNS for Anxiety in ASD

NCT NCT06258590

Start 2024-04-04

View Details →

Trial COMPLETED

ETNA-MS Device Validation Study

NCT NCT06256731

Start 2023-12-12

View Details →

Trial RECRUITING

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

NCT NCT06253494

Start 2024-05-14

View Details →

Page 872 of 959

↑